Other News Releases in Biotechnology
Raptor Pharmaceutical Corp. to Present Cystinosis Research at Lysosomal Disease Network's 2010 WORLD Symposium
Indiana Biopharmaceutical Service Providers Maintain Steady Growth Despite Industry Challenges
Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
Other News Releases in Trade Show News
ROGOV Design's New Desk Architecture Elevates Function to Fine Art
Portola Pharmaceuticals Announces Late-Breaker Presentation on Betrixaban at American College of Cardiology's 59th Annual Scientific Session
Juicy Development Unveils Disneyland(R) App at MacWorld 2010
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
See more news releases in: Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Trade Show News
Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
SAN DIEGO, Nov. 5, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the 18th Annual Credit Suisse Healthcare Conference in Phoenix, Arizona on Wednesday, November 11, 2009 at 10:00 a.m. PT / 1:00 p.m. ET. Mark Foletta, senior vice president of finance and chief financial officer at Amylin Pharmaceuticals, will be providing a corporate overview.
The audio portion of the presentation will be webcast and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate Web site, located at www.amylin.com. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.
RELATED LINKS
http://www.amylin.com